387 related articles for article (PubMed ID: 34197281)
1. Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomized, double-blind, placebo-controlled, Phase I trial.
Zhang J; Hu Z; He J; Liao Y; Li Y; Pei R; Fang X; Zeng P; Fan R; Ou Z; Deng J; Zhou J; Guan W; Min Y; Deng F; Peng H; Zhang Z; Feng C; Xin B
Emerg Microbes Infect; 2021 Dec; 10(1):1589-1597. PubMed ID: 34197281
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial.
Shu YJ; He JF; Pei RJ; He P; Huang ZH; Chen SM; Ou ZQ; Deng JL; Zeng PY; Zhou J; Min YQ; Deng F; Peng H; Zhang Z; Wang B; Xu ZH; Guan WX; Hu ZY; Zhang JK
Chin Med J (Engl); 2021 Jul; 134(16):1967-1976. PubMed ID: 34310400
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
Yang S; Li Y; Dai L; Wang J; He P; Li C; Fang X; Wang C; Zhao X; Huang E; Wu C; Zhong Z; Wang F; Duan X; Tian S; Wu L; Liu Y; Luo Y; Chen Z; Li F; Li J; Yu X; Ren H; Liu L; Meng S; Yan J; Hu Z; Gao L; Gao GF
Lancet Infect Dis; 2021 Aug; 21(8):1107-1119. PubMed ID: 33773111
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial.
Xia S; Zhang Y; Wang Y; Wang H; Yang Y; Gao GF; Tan W; Wu G; Xu M; Lou Z; Huang W; Xu W; Huang B; Wang H; Wang W; Zhang W; Li N; Xie Z; Ding L; You W; Zhao Y; Yang X; Liu Y; Wang Q; Huang L; Yang Y; Xu G; Luo B; Wang W; Liu P; Guo W; Yang X
Lancet Infect Dis; 2021 Jan; 21(1):39-51. PubMed ID: 33069281
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of the COVID-19 mRNA vaccine CS-2034: A randomized, double-blind, dose-exploration, placebo-controlled multicenter Phase I clinical trial in healthy Chinese adults.
Jin Z; Wu J; Wang Y; Huang T; Zhao K; Liu J; Wang H; Zhu T; Gou J; Huang H; Wu X; Yin H; Song J; Li R; Zhang J; Li L; Chen J; Li X; Zhang M; Li J; Hou M; Song Y; Wang B; Gao Q; Wu L; Kong Y; Dong R
J Infect; 2023 Dec; 87(6):556-570. PubMed ID: 37898410
[TBL] [Abstract][Full Text] [Related]
7. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.
Richmond P; Hatchuel L; Dong M; Ma B; Hu B; Smolenov I; Li P; Liang P; Han HH; Liang J; Clemens R
Lancet; 2021 Feb; 397(10275):682-694. PubMed ID: 33524311
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
Zhu F; Zhuang C; Chu K; Zhang L; Zhao H; Huang S; Su Y; Lin H; Yang C; Jiang H; Zang X; Liu D; Pan H; Hu Y; Liu X; Chen Q; Song Q; Quan J; Huang Z; Zhong G; Chen J; Han J; Sun H; Cui L; Li J; Chen Y; Zhang T; Ye X; Li C; Wu T; Zhang J; Xia NS
Lancet Respir Med; 2022 Aug; 10(8):749-760. PubMed ID: 35644168
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and Safety of a 3-Dose Regimen of a SARS-CoV-2 Inactivated Vaccine in Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.
Liu J; Huang B; Li G; Chang X; Liu Y; Chu K; Hu J; Deng Y; Zhu D; Wu J; Zhang L; Wang M; Huang W; Pan H; Tan W
J Infect Dis; 2022 May; 225(10):1701-1709. PubMed ID: 34958382
[TBL] [Abstract][Full Text] [Related]
11. Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2.
Sun S; Cai Y; Song TZ; Pu Y; Cheng L; Xu H; Sun J; Meng C; Lin Y; Huang H; Zhao F; Zhang S; Gao Y; Han JB; Feng XL; Yu DD; Zhu Y; Gao P; Tang H; Zhao J; Zhang Z; Yang J; Hu Z; Fu YX; Zheng YT; Peng H
Cell Res; 2021 Sep; 31(9):1011-1023. PubMed ID: 34267349
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, safety, and immunogenicity of SARS-CoV-2 mRNA vaccine (Omicron BA.5) LVRNA012: a randomized, double-blind, placebo-controlled phase 3 trial.
Zhou H; Zheng H; Peng Y; Su Y; Yu X; Wang W; Li S; Ding Y; Jiao S; Wang Y; Zhu X; Luo L; Dong Z; Liu L; Zhang F; Wu Q; Li J; Zhu F
Front Immunol; 2024; 15():1407826. PubMed ID: 38903523
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
Logunov DY; Dolzhikova IV; Shcheblyakov DV; Tukhvatulin AI; Zubkova OV; Dzharullaeva AS; Kovyrshina AV; Lubenets NL; Grousova DM; Erokhova AS; Botikov AG; Izhaeva FM; Popova O; Ozharovskaya TA; Esmagambetov IB; Favorskaya IA; Zrelkin DI; Voronina DV; Shcherbinin DN; Semikhin AS; Simakova YV; Tokarskaya EA; Egorova DA; Shmarov MM; Nikitenko NA; Gushchin VA; Smolyarchuk EA; Zyryanov SK; Borisevich SV; Naroditsky BS; Gintsburg AL;
Lancet; 2021 Feb; 397(10275):671-681. PubMed ID: 33545094
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of the SARS-CoV-2 LYB001 RBD-based VLP vaccine (CHO cell) phase 1 in Chinese adults: a randomized, double-blind, positive-parallel-controlled study.
Tang R; Zeng Y; Zhou Y; Liang Q; Kang W; Yang Z; Zheng X; Zang X; Pan H; Jin J; Zhu F
Expert Rev Vaccines; 2024; 23(1):498-509. PubMed ID: 38695310
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study.
Li J; Hui A; Zhang X; Yang Y; Tang R; Ye H; Ji R; Lin M; Zhu Z; Türeci Ö; Lagkadinou E; Jia S; Pan H; Peng F; Ma Z; Wu Z; Guo X; Shi Y; Muik A; Şahin U; Zhu L; Zhu F
Nat Med; 2021 Jun; 27(6):1062-1070. PubMed ID: 33888900
[TBL] [Abstract][Full Text] [Related]
17. The safety, immunogenicity, and efficacy of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: a randomized, open-label, active-controlled phase 3 trial.
Zhou C; Qiu Y; Wang J; Zhong X; Zhu X; Huang X; Yang L; Ji Q; Zhou F; Wu S; Yang M; Zhang J; Liu K; Ji L; Yang H; Li C; Zhao Y
Emerg Microbes Infect; 2024 Dec; 13(1):2320913. PubMed ID: 38860446
[TBL] [Abstract][Full Text] [Related]
18. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.
Xia S; Duan K; Zhang Y; Zhao D; Zhang H; Xie Z; Li X; Peng C; Zhang Y; Zhang W; Yang Y; Chen W; Gao X; You W; Wang X; Wang Z; Shi Z; Wang Y; Yang X; Zhang L; Huang L; Wang Q; Lu J; Yang Y; Guo J; Zhou W; Wan X; Wu C; Wang W; Huang S; Du J; Meng Z; Pan A; Yuan Z; Shen S; Guo W; Yang X
JAMA; 2020 Sep; 324(10):951-960. PubMed ID: 32789505
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
[TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability, and immunogenicity of a CpG/Alum adjuvanted SARS-CoV-2 recombinant protein vaccine (ZR202-CoV) in healthy adults: Preliminary report of a phase 1, randomized, double-blind, placebo-controlled, dose-escalation trial.
Feng GW; Wang ZF; He P; Lan QY; Ni L; Yang YZ; Wang CF; Cui TT; Huang LL; Yan YQ; Jiang ZW; Yang Q; Yu BW; Han X; Chen JJ; Yang SY; Yuan L; Zhou LY; Liu G; Li K; Huang Z; Zhao JC; Hu ZY; Xie ZQ
Hum Vaccin Immunother; 2023 Aug; 19(2):2262635. PubMed ID: 37881130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]